Japan is one of the world’s largest pharmaceutical markets—generally regarded as the second-largest globally. Like their US counterparts, Japanese pharmaceutical companies continue to face significant pipeline replenishment needs as global patent cliffs, pricing pressure, and internal R&D productivity challenges intensify.
Locust Walk examined China’s antibody-drug conjugate (ADC) pipeline, from target and payload trends to next-generation modalities and select ASCO 2026 readouts, to assess what it means for oncology drug development and pharma BD.
Locust Walk examined how regional licensing trends are evolving and potential deal strategies to navigate uncertainty amid three converging regulatory shifts: the U.S. Most‑Favored Nation (MFN) Executive Order and proposed GLOBE/GUARD rules, the EU Pharmaceutical Package, and Japan’s NHI pricing reform.
Locust Walk examined the evolving landscape of cross-border transactions involving Chinese biotech and what it truly takes to succeed as a global dealmaker in today’s market.
Locust Walk conducted a multi‑year analysis of JPM‑week deal activity to evaluate whether early‑January partnering and M&A activity can reliably benchmark and anticipate full‑year dealmaking momentum across global biopharma.
Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline.
The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry.
While these key pillars are not exhaustive and approaches may overlap between multiple, these areas have seen a great deal of innovation and attention from strategics and investors as a result.
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally